Orchid Pharma Limited has informed the Exchange regarding 'Intimation on receipt of EIR after the USFDA inspection at the plant of the company situated at Alathur '.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma has received the Establishment Inspection Report (EIR) from the US FDA after the inspection of its manufacturing plant located at Alathur. An EIR is issued by the US FDA once it closes an inspection of a drug manufacturing facility. Closure of the inspection with an EIR generally means the US FDA has completed its review of the facility. The company has informed the stock exchange about this development. Specific classification of the EIR (such as 'Voluntary Action Indicated' or 'Official Action Indicated') is not mentioned in the headline.
This is a routine regulatory update that signals the closure of a US FDA inspection at Orchid Pharma's Alathur facility. For shareholders, receipt of an EIR reduces uncertainty around the plant's compliance status and supports continued business with US-based customers. The stock may see a mildly positive reaction, though the tone of the EIR (clean vs. observations) will determine the actual market impact.